ECSP22026478A - Inhibidor de diacilglicerol aciltransferasa 2 - Google Patents

Inhibidor de diacilglicerol aciltransferasa 2

Info

Publication number
ECSP22026478A
ECSP22026478A ECSENADI202226478A ECDI202226478A ECSP22026478A EC SP22026478 A ECSP22026478 A EC SP22026478A EC SENADI202226478 A ECSENADI202226478 A EC SENADI202226478A EC DI202226478 A ECDI202226478 A EC DI202226478A EC SP22026478 A ECSP22026478 A EC SP22026478A
Authority
EC
Ecuador
Prior art keywords
diacylglycerol
acytransferase
inhibitor
inhibitors
dgat2
Prior art date
Application number
ECSENADI202226478A
Other languages
English (en)
Inventor
Kentaro Futatsugi
David James Edmonds
Daniel Jonathan Smaltz
Kevin James Filipski
Michelle Renee Garnsey
Jack Chang Hung Lee
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP22026478A publication Critical patent/ECSP22026478A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen compuestos de la Fórmula (I) en donde R1, R2, R3, R4, R5, R6, R7, R8 y R9 se definen en la presente, su uso como inhibidores de diacilglicerol aciltransferasa 2 (DGAT2), composiciones farmacéuticas que contienen dichos inhibidores y el uso de dichos inhibidores para tratar, por ejemplo, NASH.
ECSENADI202226478A 2019-10-04 2022-04-04 Inhibidor de diacilglicerol aciltransferasa 2 ECSP22026478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962911094P 2019-10-04 2019-10-04
US202063074123P 2020-09-03 2020-09-03

Publications (1)

Publication Number Publication Date
ECSP22026478A true ECSP22026478A (es) 2022-05-31

Family

ID=72826929

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202226478A ECSP22026478A (es) 2019-10-04 2022-04-04 Inhibidor de diacilglicerol aciltransferasa 2

Country Status (17)

Country Link
US (2) US11471458B2 (es)
EP (1) EP4038060B1 (es)
JP (1) JP7161081B2 (es)
KR (1) KR20220079906A (es)
CN (1) CN114787146A (es)
AU (1) AU2020358955B2 (es)
CA (1) CA3095028A1 (es)
CL (1) CL2022000835A1 (es)
CO (1) CO2022004286A2 (es)
CR (1) CR20220139A (es)
EC (1) ECSP22026478A (es)
ES (1) ES2966340T3 (es)
IL (1) IL291763A (es)
MX (1) MX2022004035A (es)
PE (1) PE20221444A1 (es)
TW (1) TWI771766B (es)
WO (1) WO2021064590A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202229243A (zh) 2020-10-08 2022-08-01 美商默沙東藥廠 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備
CN115429810B (zh) * 2021-06-03 2024-03-08 苏州禾研生物技术有限公司 异黄酮类化合物在制备预防或治疗酒精性肝损伤或解酒保肝的药物中的用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EA200200779A1 (ru) 1998-05-04 2002-12-26 Пфайзер Продактс Инк. Способ получения композиции, содержащей гигромицин а и эпигигромицин
CA2336714A1 (en) 1998-07-06 2000-01-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ATE437870T1 (de) 2004-05-12 2009-08-15 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
US20110319379A1 (en) 2009-03-11 2011-12-29 Corbett Jeffrey W Substituted Indazole Amides And Their Use As Glucokinase Activators
PT2406253E (pt) 2009-03-11 2013-09-11 Pfizer Derivados de benzofuranilo utilizados como inibidores de glucocinase
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2421833B1 (en) * 2009-04-21 2015-01-14 Nerviano Medical Sciences S.r.l. Resorcinol derivatives as hsp90 inhibitors
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
EP2427450A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
SG175995A1 (en) 2009-06-05 2011-12-29 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
WO2013137628A1 (ko) 2012-03-16 2013-09-19 한국생명공학연구원 신규한 디아실글리세롤 아실트랜스퍼레이즈 2 억제 물질 및 이의 이용
EP2834238B1 (en) * 2012-04-06 2017-02-01 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
MA39753B1 (fr) * 2014-03-17 2018-10-31 Pfizer Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
US10568876B2 (en) 2014-09-05 2020-02-25 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
EP3188731B1 (en) 2014-09-05 2019-04-03 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CU24573B1 (es) 2016-12-16 2022-01-13 Pfizer Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas
JP2022058085A (ja) * 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ

Also Published As

Publication number Publication date
CN114787146A (zh) 2022-07-22
US20210100798A1 (en) 2021-04-08
US11471458B2 (en) 2022-10-18
AU2020358955B2 (en) 2023-08-17
CA3095028A1 (en) 2021-04-04
EP4038060A1 (en) 2022-08-10
AU2020358955A1 (en) 2022-04-21
CR20220139A (es) 2022-05-06
KR20220079906A (ko) 2022-06-14
US11065249B2 (en) 2021-07-20
JP2022543499A (ja) 2022-10-12
ES2966340T3 (es) 2024-04-22
EP4038060C0 (en) 2023-11-15
EP4038060B1 (en) 2023-11-15
TW202126635A (zh) 2021-07-16
TWI771766B (zh) 2022-07-21
PE20221444A1 (es) 2022-09-21
CO2022004286A2 (es) 2022-04-29
WO2021064590A1 (en) 2021-04-08
MX2022004035A (es) 2022-05-02
US20210100796A1 (en) 2021-04-08
JP7161081B2 (ja) 2022-10-25
CL2022000835A1 (es) 2023-01-27
IL291763A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
BR112019002610A2 (pt) piridopirimidinonas inibidoras de cdk2/4/6
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
BR112017009601B8 (pt) Derivados de aminoácidos e composição que os compreende
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
CO2018010787A2 (es) Compuesto de griseofulvina
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
AR125457A2 (es) Compuestos inhibidores dobles de magl y faah y composición farmacéutica
CL2020002217A1 (es) Uso de alcoxipirazoles como inhibidores de la nitrificación
BR112022000936A2 (pt) Inibidores de enzimas
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
BR112019021323A2 (pt) Inibidores heterocíclicos da biossíntese de lisina através da via do diaminopimelato
CR20190391A (es) Derivados de pirazol como inhibidores de bromodominio
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo